Foghorn Therapeutics Inc. Analyst EPS Estimates
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|---|---|---|---|
| Q1 2024 | 1 | -$0.63 | -$0.63 | -$0.63 |
| Q2 2024 | 3 | -$0.64 | -$0.64 | -$0.64 |
| Q3 2024 | 5 | -$0.50 | -$0.36 | -$0.43 |
| Q4 2024 | 3 | -$0.44 | -$0.44 | -$0.44 |
| Q1 2025 | 4 | -$0.29 | -$0.29 | -$0.29 |
| Q2 2025 | 4 | -$0.30 | -$0.30 | -$0.30 |
| Q3 2025 | 4 | -$0.26 | -$0.26 | -$0.26 |
| Q4 2025 | 4 | -$0.24 | -$0.24 | -$0.24 |
Foghorn Therapeutics Inc. Earnings Date And Information
Foghorn Therapeutics Inc. last posted its earnings results on Monday, November 4th, 2024. The company reported $-0.31 earnings per share for the quarter, topping analysts' consensus estimates of $-0.42 by $0.11. The company had revenue of 7.81 M for the quarter and had revenue of 34.16 M for the year. Foghorn Therapeutics Inc. has generated $-2 earnings per share over the last year ($-2.34 diluted earnings per share) and currently has a price-to-earnings ratio of -6135.18. Foghorn Therapeutics Inc. has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, November 7th, 2024 based on prior year's report dates.
Foghorn Therapeutics Inc. Earnings History by Quarter
| Date | Quarter | Consensus Estimate | Reported EPS | Beat/Miss | Revenue Estimate | Actual Revenue |
|---|---|---|---|---|---|---|
| 11/04/2024 | Q3 2024 | -$0.42 | -$0.00 | 0.42 | $6.34 M | $7.81 M |
| 08/08/2024 | Q2 2024 | -$0.60 | -$0.45 | 0.15 | $6.04 M | $6.89 M |
| 05/06/2024 | Q1 2024 | -$0.55 | -$0.59 | -0.04 | $5.05 M | |
| 03/07/2024 | Q4 2023 | -$0.79 | -$0.57 | 0.22 | $5.77 M | |
| 11/02/2023 | Q3 2023 | -$0.72 | -$0.34 | 0.38 | $4.58 M | $17.48 M |
| 08/04/2023 | Q2 2023 | -$0.73 | -$0.70 | 0.03 | $6.32 M | $5.60 M |
| 05/08/2023 | Q1 2023 | -$0.68 | -$0.73 | -0.05 | $5.31 M | |
| 03/09/2023 | Q4 2022 | -$0.59 | -$0.82 | -0.23 | $4.18 M | |
| 11/08/2022 | Q3 2022 | -$0.60 | -$0.56 | 0.04 | $9.19 M | $6.63 M |
| 08/09/2022 | Q2 2022 | -$0.53 | -$0.66 | -0.13 | $9.58 M | $4.49 M |
| 05/09/2022 | Q1 2022 | -$0.40 | -$0.63 | -0.23 | $3.92 M | |
| 03/10/2022 | Q4 2021 | -$0.74 | $4.62 | 5.36 | $713,000 | |
| 11/09/2021 | Q3 2021 | -$0.66 | -$0.71 | -0.05 | $30,750 | $41,000 |
| 08/10/2021 | Q2 2021 | -$0.63 | -$0.63 | 0 | $279,000 | $279,000 |
| 05/11/2021 | Q1 2021 | -$0.63 | -$0.62 | 0.01 | $286,000 | |
| 03/18/2021 | Q4 2020 | -$0.45 | -$0.00 | 0.45 | $251,000 | |
| 12/04/2020 | Q3 2020 | -$1.72 | -$0.51 | 1.21 | $626,333 | $179,000 |
| 06/29/2020 | Q2 2020 | -$0.71 | $0 | |||
| 03/30/2020 | Q1 2020 | -$0.63 | $0 | |||
| 12/30/2019 | Q4 2019 | -$0.69 | $0 |
Foghorn Therapeutics Inc. Earnings: Frequently Asked Questions
-
When is Foghorn Therapeutics Inc.'s earnings date?
Foghorn Therapeutics Inc. has not confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, November 7th, 2024 based off last year's report dates.
-
Did Foghorn Therapeutics Inc. beat their earnings estimates last quarter?
In the previous quarter, Foghorn Therapeutics Inc. (:FHTX) reported $-0.31 earnings per share (EPS) to beat the analysts' consensus estimate of $-0.42 by $0.11.
-
How can I listen to Foghorn Therapeutics Inc.'s earnings conference call?
The conference call for Foghorn Therapeutics Inc.'s latest earnings report can be listened to online.
-
How can I read Foghorn Therapeutics Inc.'s conference call transcript?
The conference call transcript for Foghorn Therapeutics Inc.'s latest earnings report can be read online.
-
How much revenue does Foghorn Therapeutics Inc. generate each year?
Foghorn Therapeutics Inc. (:FHTX) has a recorded annual revenue of $34.16 M.
-
How much profit does Foghorn Therapeutics Inc. generate each year?
Foghorn Therapeutics Inc. (:FHTX) has a recorded net income of $34.16 M. Foghorn Therapeutics Inc. has generated $-2.34 earnings per share over the last four quarters.
-
What is Foghorn Therapeutics Inc.'s price-to-earnings ratio?
Foghorn Therapeutics Inc. (:FHTX) has a price-to-earnings ratio of -6135.18 and price/earnings-to-growth ratio is -539.9.
